SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

The ticker is trending due to significant downward price pressure and intense community debate following the circulation of a third-party statistical analysis on Reddit that downgraded the perceived probability of success for the REGAL Phase 3 trial. While many traders view the sell-off as a coordinated shakeout to clear stop-losses and accumulate shares ahead of potential clinical trial results, others are expressing concern over the lack of corporate communication during the current quiet period and the departure of prominent community members.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle shares are facing significant volatility following better-than-expected earnings results, as investors grapple with concerns over the company's aggressive AI infrastructure spending and a pre-scheduled stock-trading plan by Chairman Larry Ellison. While some traders view the pullback as a buying opportunity given the strong revenue backlog, others remain skeptical, citing ongoing negative free cash flow and broader market uncertainty.

Forgent Power Solutions, Inc. is a holding company, which engages in the design and manufacture of electrical distribution equipment used in data centers, power grid, and energy-intensive industrial facilities. It also offers powertrain solutions and standard and custom products. The company was founded on July 21, 2025 and is headquartered in Dayton, MN.

Forgent Power Solutions Inc. - Ordinary Shares - Class A

Forgent Power Solutions Inc.

Forgent Power Solutions is trending due to strong market enthusiasm following a triple-beat earnings report, which highlighted significant growth in revenue, bookings, and a record backlog. Traders are debating the stock's potential for further gains as a "picks and shovels" play in the AI data center infrastructure sector, with many dismissing recent price volatility as profit-taking or artificial suppression.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale Power shares fell sharply following a downgrade by UBS, which cited concerns over a prolonged project construction timeline, limited firm customer commitments, and significant anticipated cash burn. While retail traders debated the company's long-term potential in the nuclear energy sector, some participants expressed frustration with the stock's recent volatility and the lack of concrete commercial project announcements.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata is trending as traders analyze the impact of a share offering following strong quarterly results, with the community divided between long-term bullish sentiment based on AI growth and short-term volatility concerns driven by potential dilution and technical support levels. Competing viewpoints focus on whether the offering is a strategic balance sheet play or a signal of short-term downside, while traders closely monitor technical indicators for a potential gap fill.

Sable Offshore Corp. engages in offshore oil and gas field operations. It focuses on developing the prolific Santa Ynez Unit in federal waters offshore California. The company was founded by James C. Flores on October 16, 2020 and is headquartered in Houston, TX.

Sable Offshore Corp.

Sable Offshore shares are trending as the company completes a major $345 million share offering, which traders see as a critical de-risking event for its balance sheet and operations. Market participants are now focused on upcoming legal catalysts, including a key hearing on the company's Santa Ynez pipeline system.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

The primary catalyst for TLT is the persistent rise in Treasury yields and inflationary pressures, driven by ongoing geopolitical tensions in the Middle East and concerns over US national debt. Traders remain divided, with many expressing skepticism toward government intervention efforts like bond buybacks, while others weigh the possibility of a September rate hike against the economic impact of higher borrowing costs.

USELESS

USELESS is trending as traders speculate on its potential to achieve a multibillion-dollar market capitalization, with many comparing its growth prospects to previous successful meme coins. While some users express skepticism and label it a "shitcoin," others emphasize whale accumulation and the project's brand honesty as reasons for continued bullish sentiment.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Ford is experiencing volatility following a recent earnings report and subsequent decline, with traders debating whether the stock's pullback represents a buying opportunity or further downside toward lower support levels. Discussion is heavily focused on the company's long-term margin pressure, electric vehicle strategy, and potential competitive risks from Chinese manufacturers.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending following a blockbuster quarterly earnings report where the company significantly beat expectations, raised its full-year guidance, and surpassed a $1 trillion market valuation. Investors are reacting positively to surging demand for its core Mounjaro and Zepbound franchises, while discussion also focuses on the company's aggressive M&A strategy and the potential for its oral weight-loss drug to compete globally.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BioMarin Reports Positive Phase 3 Results For VOXZOGO

(RTTNews) - BioMarin Pharmaceutical Inc. (BMRN) on Wednesday announced positive Phase 3 results for VOXZOGO (vosoritide) in children with hypochondroplasia, with the study meeting its primary endpoint and all secondary efficacy endpoints...

BioMarin Announces Positive Results of Phase 3 VOXZOGO (vosoritide) Study in Hypochondroplasia Published in NEJM Evidence

BioMarin Announces Positive Results of Phase 3 VOXZOGO (vosoritide) Study in Hypochondroplasia Published in NEJM Evidence BioMarin Announces Positive Results of Phase 3 VOXZOGO (vosoritide) Study in Hypochondroplasia Published in NEJM Evidence PR Newswire SAN RAFAEL, Calif., Sept. 9, 2026 Detailed...

EVP At BioMarin Pharmaceutical Sells $1.16M Of Stock

Eric George Davis, EVP at BioMarin Pharmaceutical (NASDAQ:BMRN), reported an insider sell on September 3, according to a new SEC filing.
What Happened: Davis opted to sell 17,557 shares of BioMarin Pharmaceutical,read more...

RARE Stock Crashes In Worst Day Ever — ‘Pharma Bro’ Martin Shkreli Calls It ‘Very Cheap,’ Floats BioMarin Buyout 

Equity

Wall Street removed the Angelman program from valuation models, slashing price targets by as much as 76% and issuing multiple downgrades.

How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset

BMRN turns a competitive threat into a royalty stream as Ascendis pays royalties on Yuviwel sales, reshaping the economics of competition.

BioMarin to Participate in Upcoming Investor Conferences

BioMarin to Participate in Upcoming Investor Conferences BioMarin to Participate in Upcoming Investor Conferences PR Newswire SAN RAFAEL, Calif., Sept. 2, 2026 Wells Fargo 21st Annual Healthcare Conference, September 9 at 3:00 pm ESTCantor Global Healthcare Conference 2026, September 10 at 10:20 am...

4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects

ALNY, BMRN, RARE and BBIO offer rare-disease growth potential through strong products, pipeline catalysts and high unmet medical needs.

BioMarin Announces Close of the Alesta Therapeutics Acquisition

BioMarin Announces Close of the Alesta Therapeutics Acquisition BioMarin Announces Close of the Alesta Therapeutics Acquisition PR Newswire SAN RAFAEL, Calif., Sept. 1, 2026 Acquisition adds ALE1, a potential first oral therapy for hypophosphatasia to clinical pipeline SAN RAFAEL, Calif., Sept. 1...

ASND, BMRN Stocks Rise: Street Calls Patent Peace A Clean Overhang Lift, Keep Ratings Unchanged

BioMarin and Ascendis settled a global patent dispute over the achondroplasia drug Yuviwel on Sunday. 

Ascendis Pharma, Science Applications International And Other Big Stocks Moving Higher On Monday

U.S. stocks were lower, with the Dow Jones index falling around 400 points on Monday.

Shares of Ascendis Pharma A/S (NASDAQ:ASND) rose sharply on Monday.

On Sunday, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)read more...

BioMarin Pharmaceutical, Inc. is a global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. The company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.

Biomarin Pharmaceutical Inc. - Registered Shares

Bearish Sentiment

President Trump has promised to issue a $5,000 "dividend" check to every adult American citizen if the Republican Party wins control of both the House and the Senate in the upcoming midterm elections, though the proposal would require congressional approval and follows his earlier $2,000 tariff-dividend plan, which stalled after the Supreme Court struck down much of his tariff authority. Do you think the $5,000 dividend check actually happens? Vote and explain your reasoning in the comments.

Trump has pledged a $5,000 &quot;dividend&quot; check to every adult American citizen if Republicans win control of both the House and Senate in the midterms. Do you think it actually happens?

Stocktwits

Trump has pledged a $5,000 "dividend" check to every adult American citizen if Republicans win control of both the House and Senate in the midterms. Do you think it actually happens?

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	$1.33	--	--	N/A
Q2 '26	$0.95	$1.20	26.98%	BEAT
Q1 '26	$0.69	$0.76	9.59%	BEAT
Q4 '25	$0.17	-$0.24	-241.66%	MISSED
Q3 '25	$0.81	-$0.16	-119.77%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

BMRN Earnings

Upcoming Earnings: Q3 '26

Historical Earnings